Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
New Strong Sell Stocks for November 22nd

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:ATI Inc. ATI is a specialty manufacturing company. The Zacks Consensus Estimate for its current year earnings has been revised...

ALTG : 7.90 (+5.19%)
ATI : 59.22 (+1.82%)
AKBA : 1.8650 (+2.47%)
Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics: Q3 Earnings Snapshot

AKBA : 1.8650 (+2.47%)
Talis: Q2 Earnings Snapshot

Talis: Q2 Earnings Snapshot

AKBA : 1.8650 (+2.47%)
Akebia Therapeutics: Q2 Earnings Snapshot

Akebia Therapeutics: Q2 Earnings Snapshot

AKBA : 1.8650 (+2.47%)
Akebia Therapeutics: Q1 Earnings Snapshot

Akebia Therapeutics: Q1 Earnings Snapshot

AKBA : 1.8650 (+2.47%)
Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics: Q3 Earnings Snapshot

AKBA : 1.8650 (+2.47%)
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8650 (+2.47%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8650 (+2.47%)
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8650 (+2.47%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8650 (+2.47%)

Barchart Exclusives

Attention Long-Time SoFi Technologies Shareholders: Thursday's Unusual Options Activity Could Guide Your Next Investment Move
Title: Summary: SoFi Technologies had the third-highest Vol/OI ratio in Thursday’s options trading. It was one of 20 unusually active options for the fintech growth stock. If you bought SOFI stock at the 2022 lows, it could be time to get protective. $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ A couple of interesting economic data points... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar